Evidence map›Paper›PMID 42578741›Full record

ArticleRheumatology (Oxford, England)2026

Early haematologic response to anifrolumab in SLE: results from the European multicentre EFFORT-SLE study.

Michela Gasparotto, Alessandra Bettiol, Ginevra De Marchi, Edoardo Biancalana, Giulia Duro, Filippo Fagni, Alice Horisberger, Joško Mitrović, Alessia Nano, Katarzyna Wawrzycka-Adamczyk and 11 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Rheumatology (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Michela GasparottoDepartment of Medical, Surgery and Health Sciences, University of Trieste, Italy and Clinical Medicine and Rheumatology Unit, Cattinara University Hospital, Trieste, Italy.
Alessandra BettiolDepartment of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Florence, Italy.
Ginevra De MarchiRheumatology Division, Department of Medicine, University of Udine and Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy.
Edoardo BiancalanaDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Giulia DuroDepartment of Medical, Surgery and Health Sciences, University of Trieste, Italy and Clinical Medicine and Rheumatology Unit, Cattinara University Hospital, Trieste, Italy.
Filippo FagniDepartment of Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Universitaetsklinikum Erlangen, Erlangen, Germany.ORCID 0000-0002-6122-0774
Alice HorisbergerCentre Hospitalier Universitaire Vaudois, Immunology and Allergy Service, University of Lausanne, Lausanne, Switzerland.
Joško MitrovićDivision of Clinical Immunology, Allergology and Rheumatology, Department of Internal Medicine, Dubrava University Hospital, and University of Zagreb, School of Medicine, Faculty of Pharmacy and Biochemistry, Zagreb, Croatia.
Alessia NanoRheumatology Division, Department of Medicine, University of Udine and Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy.
Katarzyna Wawrzycka-AdamczykCenter for the Development of Therapies for Civilization and Age Related Diseases, Jagiellonian University Medical College, Cracow, Poland.
Myriam ReischDivision of Rheumatology and Clinical Immunology, Medical University of Graz, Graz, Austria.
Lea SalamonDivision of Clinical Immunology, Allergology and Rheumatology, Department of Internal Medicine, Dubrava University Hospital, and University of Zagreb, School of Medicine, Faculty of Pharmacy and Biochemistry, Zagreb, Croatia.
Georg SchettDepartment of Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Universitaetsklinikum Erlangen, Erlangen, Germany.
Ladislav ŠenoltInstitute of Rheumatology and First Faculty of Medicine, Charles University, Prague, Czech Republic.
Elena SilvestriDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Jens ThielDivision of Rheumatology and Clinical Immunology, Medical University of Graz, Graz, Austria.
Paola TomiettoDepartment of Medical, Surgery and Health Sciences, University of Trieste, Italy and Clinical Medicine and Rheumatology Unit, Cattinara University Hospital, Trieste, Italy.
Krzysztof Wójcik2nd Department of Internal Medicine, Faculty of Medicine, Jagiellonian University Medical College, Cracow, Poland.ORCID 0000-0001-9786-2499
Jakub ZávadaInstitute of Rheumatology and First Faculty of Medicine, Charles University, Prague, Czech Republic.
Luca QuartuccioRheumatology Division, Department of Medicine, University of Udine and Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy.
Giacomo EmmiDepartment of Medical, Surgery and Health Sciences, University of Trieste, Italy and Clinical Medicine and Rheumatology Unit, Cattinara University Hospital, Trieste, Italy.

Funding

MHCR 023728
6 · The paper itself

Abstract

objectivesTo evaluate the efficacy and safety of anifrolumab (ANI) for the haematologic manifestations of SLE in routine clinical practice.

methodsIn this retrospective multicentre European study, adult patients with SLE presenting with ≥1 disease-related haematologic abnormality at ANI initiation were included. Clinical and laboratory data were collected at baseline and at 3, 6, 12, 18 and 24 months. Complete haematologic response (CHR) was defined as normalization of all baseline abnormalities, whereas partial haematologic response (PHR) was defined as normalization of at least one affected lineage.

resultsForty-seven patients from seven European countries were included (91.5% female). ANI was specifically initiated for haematologic involvement in 21/47 (44.7%), whereas 26/47 (55.3%) started treatment for other SLE manifestations but had ≥1 haematologic abnormality at baseline. CHR was achieved in 8/43 (18.6%) patients at 3 months and cumulatively in 14/46 (30.4%) within 6 months (overall 17/47, 36.2%), with comparable rates regardless of treatment indication. PHR occurred in 17/43 (39.5%) at 3 months and in 11/37 (29.7%) at 6 months. Haemoglobin, leucocyte and lymphocyte counts significantly improved by month 3, whereas platelet counts showed a non-significant increase. Higher baseline CRP, ESR and SLE-DAS were associated with the lack of CHR. Twelve patients (25.5%) discontinued ANI, and 17 (36.2%) experienced adverse events without discontinuation.

conclusionANI was associated with early haematologic improvement, with one-third of patients achieving complete normalization under a stringent definition of remission. Responses involved multiple haematologic lineages and were less frequent in patients with higher inflammatory activity, although confirmation in broader populations is warranted.

Indexed as

Antibodies, Monoclonal, HumanizedLupus Erythematosus, SystemicAdultEuropeFemaleHumansMaleMiddle AgedRetrospective StudiesThrombocytopeniaTreatment OutcomeanifrolumabAntibodies, Monoclonal, Humanizedanaemiaanifrolumabautoimmune haemolytic anaemiacytopeniaIFNlymphopeniaobservational studySLEthrombocytopeniatreatment outcome

Identifiers

PMID42578741
PMCPMC13544960

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.